People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| SIRPant Immunotherapeutics, Inc. | — | Biotechnology | Series B | $32.4M | $28.7M | 2025 |
Robert C. Towarnicki at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert C. Towarnicki on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rifat Pamukcu | 1 | 4 |
| John Fucci | 1 | 3 |
| Travis Whitfill | 1 | 3 |
| Stephen C. Rocamboli | 1 | 3 |
| Roger Sawhney | 1 | 2 |
| Robert Towarnicki | 1 | 1 |
| Travis Whitfull | 1 | 1 |
| Roger C. Sawhney | 1 | 1 |
| Tim C. Van Treuren | 1 | 1 |
| Rifat C. Pamukcu | 1 | 1 |
| Tim Van Treuren | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.